HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
1,2,3,7,8-Pentachlorodibenzo-p-dioxin
1,2,3,7,8-PCDD · 1,2,3,7,8-PNCDD · 1,2,3,7,8-PECDD · 1,2,3,7,8-Pentachlorooxanthrene · 1,2,3,7,8-PENTACHLORODIBENZODIOXIN · Pentachlorobenzo-p-dioxin, 1,2,3,7,8- · 1,2,3,7,8-pentachloro-dibenzo-p-dioxi · 2,3,4,7,8-Pentachlorodibenzo[1,4]dioxin
Identifikatoren & physikalische Daten
| CAS No. | 40321-76-4 |
|---|---|
| Summenformel | C12H3Cl5O2 |
| Durchschnittliche Molmasse | 356,4 g/mol |
| Monoisotopische Masse | 353,857568 g/mol |
| SMILES | Clc1cc2c(cc1Cl)Oc1c(cc(Cl)c(Cl)c1Cl)O2 |
| InChIKey | FSPZPQQWDODWAU-UHFFFAOYSA-N |
| PubChem CID | 38439 |
| ChEMBL | CHEMBL137220 |
| ChEBI | CHEBI:81501 |
| EC No. | 694-814-9 |
| DTXSID | DTXSID7052078 |
Chemische & physikalische Eigenschaften
| XLogP | 6,6 |
|---|---|
| Polarare Oberfläche (TPSA) | 18,5 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 0 |
| Schwere Atome | 19 |
| Formalladung | 0 |
| Komplexität | 344 |
| SpringerMaterials Properties | Boiling point |
| LogP (Verteilungskoeffizient) | 6.64 |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Collision Cross Section | 165.2 Ų [M]+ [CCS Type: TIMS, Method: calibration with PAHs] |
| Schmelzpunkt | 206°C (estimate) |
| Siedepunkt | 442.63°C (rough estimate) |
| Dichte | 1.7800 (estimate) |
| Brechungsindex | 1.6610 (estimate) |
| Löslichkeit | n-nonane: Soluble |
| Henry-Konstante | 5.2×10-5 mol/(m3Pa) at 25℃, Paasivirta et al. (1999) |
| EPA chemische Informationen | 1,2,3,7,8-Pentachlorodibenzo-p-dioxin (40321-76-4) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]P264, P270, P273, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Hazard Traits - BioaccumulationCarcinogenicityDermatotoxicityEndocrine ToxicityEnvironmental PersistenceEnvironmental toxHematotoxicityHepatotoxicity and Digestive System ToxicityReproductive ToxicityRespiratory ToxicityRegulation (EC) No 178/2002 (amended) |
| Hazard Classes and Categories | Acute Tox. 1 (100%) |
| Minimum Risk Level | Acute Oral: 0.0002 ug/kg/day (L134) Intermediate Oral: 0.00002 ug/kg/day (L134) Chronic Oral: 0.000001 ug/kg/day (L134) |
| Protective Action Criteria (PAC) | 0.00013 [mg/m3]0.0014 [mg/m3]0.0085 [mg/m3] |
| Treatment | Treatment of CDD exposure may include washing the area of contact, GI decontamination, administering an IV, or forced alkaline diuresis. (L346) |
| Gesundheitliche Auswirkungen | Exposure to large amounts of CDDs causes chloracne, a severe skin disease with acne-like lesions that occur mainly on the face and upper body. CDDs may also cause liver damage and induce long-term alterations in glucose metabolism and subtle changes in hormonal levels. In addition, studies have shown that CDDs may disrupt the endocrine system and weaken the immune system, as well as cause reproductive damage and birth defects, central and peripheral nervous system pathology, thyroid disorders, endometriosis, and diabetes. (L177, L178) |
| Expositionspfade | Oral (L177)inhalation(L177)dermal (L177) |
Anwendungen & Verwendung
Verwenden
A toxic polychlorinated dibenzo-p-dioxin detected in domestic meat and poultry.